Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making
The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now
Already have access? Login below
